Kristina Öbrink-Hansen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kristina Öbrink-Hansen has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Mats Bue
Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
6 shared publications - Pelle Hanberg
Department of Otorhinolaryngology, Head and Neck Surgery, Aarhus University Hospital, Aarhus, Denmark
5 shared publications - Maiken Stilling
Aarhus University Hospital
4 shared publications - Andrea René Jørgensen
Aarhus Microdialysis Research Group, Orthopaedic Research Unit, Aarhus University Hospital, Aarhus N, Denmark
3 shared publications - Sara Kousgaard Tøstesen
Aarhus Denmark Microdialysis Research (ADMIRE), Orthopaedic Research Laboratory, Aarhus University Hospital, Aarhus, 8200, Denmark
3 shared publications - Elisabeth Krogsgaard Petersen
Aarhus Denmark Microdialysis Research (ADMIRE), Orthopaedic Research Laboratory (https://microdialysis.au.dk), Aarhus University Hospital, Aarhus, Denmark
2 shared publications
Latest Publications
- Open Access
- 6 August 2025
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 69 (8) , e0181124
Distribution of acyclovir in central nervous system compartments: a porcine pharmacokinetic model
Herpes simplex virus (HSV) encephalitis is a severe infection with high mortality and neurological sequelae if untreated. Intravenous acyclovir (ACV) is the standard treatment, but its central nervous system (CNS) penetration is not fully understood. To evaluate the distribution of ACV in various CNS compartments in a porcine pharmacokinetic model, 12 female pigs were divided into two groups: group I receiving a single ACV dose (10 mg/kg) and group II receiving three doses over 24 h. Microdialysis sampled unbound ACV concentrations in cortical and subcortical extracellular fluid (ECF), ventricular cerebrospinal fluid (CSF), and cisternal CSF. The ACV target concentration was defined as peak concentration ( f C max ) > inhibitory concentration 50% (IC 50 ) for HSV-1 at 0.56 µg/mL. Pharmacokinetic parameters, including f C max , time above IC 50 (T > IC 50 ), and area under the curve (AUC), were analyzed. The target ACV concentration ( f C max > 0.56 µg/mL) was achieved in all ECF and CSF compartments during the second and third dosing intervals. The T > IC 50 and AUC increased from the first to the third dose and were consistent across compartments. Intracerebral penetration ratios ( f AUC tissue / f AUC plasma ) during the third dose ranged from 0.18 to 0.32 within the CNS compartments. In conclusion, ACV administered intravenously at 10 mg/kg every eighth hour achieved therapeutic levels in porcine CNS compartments after the second dose, suggesting that current dosing regimens are effective in treating HSV encephalitis. However, the first dose may not reach therapeutic levels, suggesting that higher initial dosages or prolonged infusions should be considered. Further studies under inflammatory conditions are warranted to extrapolate these findings.
- 6 August 2025
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 69 (8) , e0181124
Open AccessDistribution of acyclovir in central nervous system compartments: a porcine pharmacokinetic model
Herpes simplex virus (HSV) encephalitis is a severe infection with high mortality and neurological sequelae if untreated. Intravenous acyclovir (ACV) is the standard treatment, but its central nervous system (CNS) penetration is not fully understood. To evaluate the distribution of ACV in various CNS compartments in a porcine pharmacokinetic model, 12 female pigs were divided into two groups: group I receiving a single ACV dose (10 mg/kg) and group II receiving three doses over 24 h. Microdialysis sampled unbound ACV concentrations in cortical and subcortical extracellular fluid (ECF), ventricular cerebrospinal fluid (CSF), and cisternal CSF. The ACV target concentration was defined as peak concentration ( f C max ) > inhibitory concentration 50% (IC 50 ) for HSV-1 at 0.56 µg/mL. Pharmacokinetic parameters, including f C max , time above IC 50 (T > IC 50 ), and area under the curve (AUC), were analyzed. The target ACV concentration ( f C max > 0.56 µg/mL) was achieved in all ECF and CSF compartments during the second and third dosing intervals. The T > IC 50 and AUC increased from the first to the third dose and were consistent across compartments. Intracerebral penetration ratios ( f AUC tissue / f AUC plasma ) during the third dose ranged from 0.18 to 0.32 within the CNS compartments. In conclusion, ACV administered intravenously at 10 mg/kg every eighth hour achieved therapeutic levels in porcine CNS compartments after the second dose, suggesting that current dosing regimens are effective in treating HSV encephalitis. However, the first dose may not reach therapeutic levels, suggesting that higher initial dosages or prolonged infusions should be considered. Further studies under inflammatory conditions are warranted to extrapolate these findings.
- Open Access
- 3 May 2024
- Published by Hindawi Limited in Case Reports in Infectious Diseases
- Vol. 2024, 1-3
Diagnostic Delay of Spinal Tuberculosis Causing Medullary Compression
We present a case of a Philippine woman in her late twenties, diagnosed with spinal tuberculosis after surgical intervention due to medullary compression. The diagnosis was preceded by four months of unexplained back pain. Differential diagnoses included ulcer, liver-gallbladder disease, musculoskeletal causes, and cancer. This case highlights the importance of considering tuberculosis as a differential diagnosis in patients from high-endemic areas to avoid diagnostic delay and the risk of disease progression.
- 3 May 2024
- Published by Hindawi Limited in Case Reports in Infectious Diseases
- Vol. 2024, 1-3
Open AccessDiagnostic Delay of Spinal Tuberculosis Causing Medullary Compression
We present a case of a Philippine woman in her late twenties, diagnosed with spinal tuberculosis after surgical intervention due to medullary compression. The diagnosis was preceded by four months of unexplained back pain. Differential diagnoses included ulcer, liver-gallbladder disease, musculoskeletal causes, and cancer. This case highlights the importance of considering tuberculosis as a differential diagnosis in patients from high-endemic areas to avoid diagnostic delay and the risk of disease progression.
- Open Access
- 20 March 2023
- Published by MDPI AG in Antibiotics
- Vol. 12 (3) , 615
Steady-State Piperacillin Concentrations in the Proximity of an Orthopedic Implant: A Microdialysis Porcine Study
Implant-associated osteomyelitis is one of the most feared complications following orthopedic surgery. Although the risk is low, sufficient antibiotic protection of the implant surface is important. The aim of this study was to assess steady-state piperacillin concentrations in the proximity of an orthopedic implant. Time above the minimal inhibitory concentration (fT>MIC) was evaluated for MIC of 8 (low target) and 16 μg/mL (high target). Six female pigs received an intravenous bolus infusion of 4 g/0.5 g piperacillin/tazobactam over 30 min every 6 h. Steady state was assumed achieved in the third dosing interval (12–18 h). Microdialysis catheters were placed in a cannulated screw in the proximal tibial cancellous bone, in cancellous bone next to the screw, and in cancellous bone on the contralateral tibia. Dialysates were collected from time 12 to 18 h and plasma samples were collected as reference. For the low piperacillin target (8 µg/mL), comparable mean fT>MIC across all the investigated compartments (mean range: 54–74%) was found. For the high target (16 µg/mL), fT>MIC was shorter inside the cannulated screw (mean: 16%) than in the cancellous bone next to the screw and plasma (mean range: 49–54%), and similar between the two cancellous bone compartments. To reach more aggressive piperacillin fT>MIC targets in relation to the implant, alternative dosing regimens such as continuous infusion may be considered.
- 20 March 2023
- Published by MDPI AG in Antibiotics
- Vol. 12 (3) , 615
Open AccessSteady-State Piperacillin Concentrations in the Proximity of an Orthopedic Implant: A Microdialysis Porcine Study
Implant-associated osteomyelitis is one of the most feared complications following orthopedic surgery. Although the risk is low, sufficient antibiotic protection of the implant surface is important. The aim of this study was to assess steady-state piperacillin concentrations in the proximity of an orthopedic implant. Time above the minimal inhibitory concentration (fT>MIC) was evaluated for MIC of 8 (low target) and 16 μg/mL (high target). Six female pigs received an intravenous bolus infusion of 4 g/0.5 g piperacillin/tazobactam over 30 min every 6 h. Steady state was assumed achieved in the third dosing interval (12–18 h). Microdialysis catheters were placed in a cannulated screw in the proximal tibial cancellous bone, in cancellous bone next to the screw, and in cancellous bone on the contralateral tibia. Dialysates were collected from time 12 to 18 h and plasma samples were collected as reference. For the low piperacillin target (8 µg/mL), comparable mean fT>MIC across all the investigated compartments (mean range: 54–74%) was found. For the high target (16 µg/mL), fT>MIC was shorter inside the cannulated screw (mean: 16%) than in the cancellous bone next to the screw and plasma (mean range: 49–54%), and similar between the two cancellous bone compartments. To reach more aggressive piperacillin fT>MIC targets in relation to the implant, alternative dosing regimens such as continuous infusion may be considered.
- Open Access
- 14 March 2023
- Published by MDPI AG in Antibiotics
- Vol. 12 (3) , 577
Piperacillin Steady State Concentrations in Target Tissues Relevant for PJI Treatment—A Randomized Porcine Microdialysis Study Comparing Continuous Infusion with Intermittent Short-Term Infusion
(1) Introduction: Piperacillin is a common antibiotic choice in the treatment of periprosthetic joint infections (PJI) caused by Pseudomonas aeruginosa. The aim of this study was to assess and compare the time with free piperacillin concentration above the minimum inhibitory concentration (fT > MIC) at steady state in target tissues relevant for PJI treatment following continuous and intermittent short-term infusion. (2) Methods: 16 pigs were randomized to receive either continuous or intermittent short-term infusion of piperacillin. Steady state piperacillin concentrations were assessed using microdialysis in tibial cortical bone, tibial cancellous bone, synovial fluid of the knee joint, and subcutaneous tissue. MIC-targets of 4, 8, 16, and 64 mg/L were applied. Plasma samples were obtained as reference. (3) Results: Continuous infusion resulted in longer fT > MIC for MIC targets of 4 mg/L and 8 mg/L compared to intermittent short-term infusion in all compartments with the exception of tibial cortical bone. For the MIC-target of 16 mg/L, continuous infusion resulted in a longer fT > MIC in all compartments except for the bone compartments. No differences between groups were seen when applying a MIC-target of 64 mg/L. (4) Conclusions: An aggressive dosing strategy may be necessary to obtain sufficient piperacillin concentrations in all bone compartments, particularly if more aggressive targets are applied. Based on the present study, continuous infusion should be considered in the treatment of PJI.
- 14 March 2023
- Published by MDPI AG in Antibiotics
- Vol. 12 (3) , 577
Open AccessPiperacillin Steady State Concentrations in Target Tissues Relevant for PJI Treatment—A Randomized Porcine Microdialysis Study Comparing Continuous Infusion with Intermittent Short-Term Infusion
(1) Introduction: Piperacillin is a common antibiotic choice in the treatment of periprosthetic joint infections (PJI) caused by Pseudomonas aeruginosa. The aim of this study was to assess and compare the time with free piperacillin concentration above the minimum inhibitory concentration (fT > MIC) at steady state in target tissues relevant for PJI treatment following continuous and intermittent short-term infusion. (2) Methods: 16 pigs were randomized to receive either continuous or intermittent short-term infusion of piperacillin. Steady state piperacillin concentrations were assessed using microdialysis in tibial cortical bone, tibial cancellous bone, synovial fluid of the knee joint, and subcutaneous tissue. MIC-targets of 4, 8, 16, and 64 mg/L were applied. Plasma samples were obtained as reference. (3) Results: Continuous infusion resulted in longer fT > MIC for MIC targets of 4 mg/L and 8 mg/L compared to intermittent short-term infusion in all compartments with the exception of tibial cortical bone. For the MIC-target of 16 mg/L, continuous infusion resulted in a longer fT > MIC in all compartments except for the bone compartments. No differences between groups were seen when applying a MIC-target of 64 mg/L. (4) Conclusions: An aggressive dosing strategy may be necessary to obtain sufficient piperacillin concentrations in all bone compartments, particularly if more aggressive targets are applied. Based on the present study, continuous infusion should be considered in the treatment of PJI.
- Open Access
- 7 July 2022
- Published by MDPI AG in Antibiotics
- Vol. 11 (7) , 910
Intermittent Short-Term Infusion vs. Continuous Infusion of Piperacillin: Steady State Concentrations in Porcine Cervical Spine Tissue Evaluated by Microdialysis
Background: Piperacillin is a central drug in the treatment of Pseudomonas aeruginosa spondylodiscitis. Intermittent short-term infusion (STI) remains standard treatment in most centres, although the application of continuous infusion (CI) has shown promising results in other clinical settings. We aimed to evaluate time above the minimal inhibitory concentration (fT > MIC) of the free fraction of piperacillin in steady state conditions in porcine cervical spine tissue following CI and STI using microdialysis with MIC targets of 4, 8, and 16 g/mL. Methods: 16 female pigs were randomized to receive piperacillin/tazobactam as STI (4/0.5 g every 6 h) or CI (4/0.5 g as a bolus followed by 12/1.5 g) for 18 h. Microdialysis catheters were placed for sampling of piperacillin concentrations from the intervertebral disc, vertebral cancellous bone, paravertebral muscle, and adjacent subcutaneous tissue during the third dosing interval (12–18 h). Blood samples were collected as reference. Results: CI resulted in fT > MIC > 82% across all compartments and targets, except for intervertebral disc (37%) and vertebral cancellous bone (28%) at MIC = 16 g/mL. In Group STI, >72% fT > MIC was reached for MIC = 4 g/mL in all investigated compartments, while for MIC = 16 g/mL only subcutaneous tissue exhibited fT > MIC > 50%. Conclusion: CI of piperacillin resulted in higher fT > MIC compared to STI infusion across the investigated tissues and targets. CI should therefore be considered in spondylodiscitis cases requiring piperacillin treatment.- 7 July 2022
- Published by MDPI AG in Antibiotics
- Vol. 11 (7) , 910
Open AccessIntermittent Short-Term Infusion vs. Continuous Infusion of Piperacillin: Steady State Concentrations in Porcine Cervical Spine Tissue Evaluated by Microdialysis
Background: Piperacillin is a central drug in the treatment of Pseudomonas aeruginosa spondylodiscitis. Intermittent short-term infusion (STI) remains standard treatment in most centres, although the application of continuous infusion (CI) has shown promising results in other clinical settings. We aimed to evaluate time above the minimal inhibitory concentration (fT > MIC) of the free fraction of piperacillin in steady state conditions in porcine cervical spine tissue following CI and STI using microdialysis with MIC targets of 4, 8, and 16 g/mL. Methods: 16 female pigs were randomized to receive piperacillin/tazobactam as STI (4/0.5 g every 6 h) or CI (4/0.5 g as a bolus followed by 12/1.5 g) for 18 h. Microdialysis catheters were placed for sampling of piperacillin concentrations from the intervertebral disc, vertebral cancellous bone, paravertebral muscle, and adjacent subcutaneous tissue during the third dosing interval (12–18 h). Blood samples were collected as reference. Results: CI resulted in fT > MIC > 82% across all compartments and targets, except for intervertebral disc (37%) and vertebral cancellous bone (28%) at MIC = 16 g/mL. In Group STI, >72% fT > MIC was reached for MIC = 4 g/mL in all investigated compartments, while for MIC = 16 g/mL only subcutaneous tissue exhibited fT > MIC > 50%. Conclusion: CI of piperacillin resulted in higher fT > MIC compared to STI infusion across the investigated tissues and targets. CI should therefore be considered in spondylodiscitis cases requiring piperacillin treatment. - 1 March 2022
- Published by Springer Nature in Pharmaceutical Research
- Vol. 39 (7) , 1633-1643
Population Pharmacokinetics of Flucloxacillin In Bone and Soft Tissue– Standard Dosing is Not Sufficient to Achieve Therapeutic Concentrations
Purpose Flucloxacillin is a β-lactam penicillin commonly used in the treatment of bone and soft tissue infections. In a recent porcine study, we found surprisingly low time for which the free concentration was maintained above the minimal inhibitory concentration (fT>MIC) in bone and soft tissue, following flucloxacillin oral (PO) and intravenous (IV) administration at 1g every 6h (q6h). In addition to plasma, sampling was obtained from subcutaneous tissue, knee joint, cancellous bone and cortical bone, using microdialysis. To identify flucloxacillin dosing regimens that result in theoretically therapeutic concentrations, we developed a population pharmacokinetic (PK) model for the porcine data, and combined it with a human flucloxacillin population PK model for simulations. Methods A four-compartment model was developed, and various dosing regimens and modes of administration were simulated. Predicted concentrations were compared to %fT>MIC (0.5 mg/L and 2 mg/L). Results Continuous infusion (CI) resulted in higher %fT>MIC compared to intermittent administration. For intermittent IV dosing (4, 8 and 12g/24h), fT>MIC (0.5 mg/L) was ≥70% in plasma, and ranged between 42-96% in the sampled tissue in a typical individual. By applying CI, 4g/day was sufficient to achieve ≥98% fT>MIC (0.5 mg/L) in all sampled tissues. For MIC 2 mg/L, ≥50% fT>MIC was only achieved in plasma at CI 8 and 12g/24h and IV 3g q6h. Conclusions To reach efficacious flucloxacillin bone and tissue concentrations, dose increment or continuous infusion needs to be considered.
- 1 March 2022
- Published by Springer Nature in Pharmaceutical Research
- Vol. 39 (7) , 1633-1643
Population Pharmacokinetics of Flucloxacillin In Bone and Soft Tissue– Standard Dosing is Not Sufficient to Achieve Therapeutic Concentrations
Purpose Flucloxacillin is a β-lactam penicillin commonly used in the treatment of bone and soft tissue infections. In a recent porcine study, we found surprisingly low time for which the free concentration was maintained above the minimal inhibitory concentration (fT>MIC) in bone and soft tissue, following flucloxacillin oral (PO) and intravenous (IV) administration at 1g every 6h (q6h). In addition to plasma, sampling was obtained from subcutaneous tissue, knee joint, cancellous bone and cortical bone, using microdialysis. To identify flucloxacillin dosing regimens that result in theoretically therapeutic concentrations, we developed a population pharmacokinetic (PK) model for the porcine data, and combined it with a human flucloxacillin population PK model for simulations. Methods A four-compartment model was developed, and various dosing regimens and modes of administration were simulated. Predicted concentrations were compared to %fT>MIC (0.5 mg/L and 2 mg/L). Results Continuous infusion (CI) resulted in higher %fT>MIC compared to intermittent administration. For intermittent IV dosing (4, 8 and 12g/24h), fT>MIC (0.5 mg/L) was ≥70% in plasma, and ranged between 42-96% in the sampled tissue in a typical individual. By applying CI, 4g/day was sufficient to achieve ≥98% fT>MIC (0.5 mg/L) in all sampled tissues. For MIC 2 mg/L, ≥50% fT>MIC was only achieved in plasma at CI 8 and 12g/24h and IV 3g q6h. Conclusions To reach efficacious flucloxacillin bone and tissue concentrations, dose increment or continuous infusion needs to be considered.
- 4 August 2020
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 102 (21) , 1857-1864
Timing of Antimicrobial Prophylaxis and Tourniquet Inflation
Background: Tourniquets are widely used during extremity surgery. In order to prevent surgical site infection, correct timing of antimicrobial prophylaxis and tourniquet inflation is important. We aimed to evaluate the time for which the free drug concentration of cefuroxime is maintained above the minimum inhibitory concentration (t > MIC) in porcine subcutaneous adipose tissue and calcaneal cancellous bone during 3 clinically relevant tourniquet application scenarios. Methods: Twenty-four female Danish Landrace pigs were included. Microdialysis catheters were placed bilaterally for sampling of cefuroxime concentrations in calcaneal cancellous bone and subcutaneous adipose tissue, and a tourniquet was applied to a randomly picked leg of each pig. Subsequently, the pigs were randomized into 3 groups to receive 1.5 g of cefuroxime by intravenous injection 15 minutes prior to tourniquet inflation (Group A), 45 minutes prior to tourniquet inflation (Group B), and at the time of tourniquet release (Group C). The tourniquet duration was 90 minutes in all groups. Dialysates and venous blood samples were collected for 8 hours after cefuroxime administration. Cefuroxime and various ischemic marker concentrations were quantified. Results: Cefuroxime concentrations were maintained above the clinical breakpoint MIC for Staphylococcus aureus (4 µg/mL) in calcaneal cancellous bone and subcutaneous adipose tissue throughout the 90-minute tourniquet duration in Groups A and B. Cefuroxime administration at the time of tourniquet release (Group C) resulted in concentrations of >4 µg/mL for approximately of 3.5 hours in the tissues on the tourniquet side. Furthermore, tourniquet application induced ischemia (increased lactate:pyruvate ratio) and cell damage (increased glycerol) in subcutaneous adipose tissue and calcaneal cancellous bone. Tissue ischemia was sustained for 2.5 hours after tourniquet release in calcaneal cancellous bone. Conclusions: Administration of cefuroxime (1.5 g) in the 15 to 45-minute window prior to tourniquet inflation resulted in sufficient concentrations in calcaneal cancellous bone and subcutaneous adipose tissue throughout the 90-minute tourniquet application. Furthermore, tourniquet-induced tissue ischemia fully resolved 2.5 hours after tourniquet release. Clinical Relevance: Cefuroxime administration 15 to 45 minutes prior to tourniquet inflation seems to be a safe window. If the goal is to maintain postoperative cefuroxime concentrations above relevant MIC values, our results suggest that a second dose of cefuroxime should be administered at the time of tourniquet release.
- 4 August 2020
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 102 (21) , 1857-1864
Timing of Antimicrobial Prophylaxis and Tourniquet Inflation
Background: Tourniquets are widely used during extremity surgery. In order to prevent surgical site infection, correct timing of antimicrobial prophylaxis and tourniquet inflation is important. We aimed to evaluate the time for which the free drug concentration of cefuroxime is maintained above the minimum inhibitory concentration (t > MIC) in porcine subcutaneous adipose tissue and calcaneal cancellous bone during 3 clinically relevant tourniquet application scenarios. Methods: Twenty-four female Danish Landrace pigs were included. Microdialysis catheters were placed bilaterally for sampling of cefuroxime concentrations in calcaneal cancellous bone and subcutaneous adipose tissue, and a tourniquet was applied to a randomly picked leg of each pig. Subsequently, the pigs were randomized into 3 groups to receive 1.5 g of cefuroxime by intravenous injection 15 minutes prior to tourniquet inflation (Group A), 45 minutes prior to tourniquet inflation (Group B), and at the time of tourniquet release (Group C). The tourniquet duration was 90 minutes in all groups. Dialysates and venous blood samples were collected for 8 hours after cefuroxime administration. Cefuroxime and various ischemic marker concentrations were quantified. Results: Cefuroxime concentrations were maintained above the clinical breakpoint MIC for Staphylococcus aureus (4 µg/mL) in calcaneal cancellous bone and subcutaneous adipose tissue throughout the 90-minute tourniquet duration in Groups A and B. Cefuroxime administration at the time of tourniquet release (Group C) resulted in concentrations of >4 µg/mL for approximately of 3.5 hours in the tissues on the tourniquet side. Furthermore, tourniquet application induced ischemia (increased lactate:pyruvate ratio) and cell damage (increased glycerol) in subcutaneous adipose tissue and calcaneal cancellous bone. Tissue ischemia was sustained for 2.5 hours after tourniquet release in calcaneal cancellous bone. Conclusions: Administration of cefuroxime (1.5 g) in the 15 to 45-minute window prior to tourniquet inflation resulted in sufficient concentrations in calcaneal cancellous bone and subcutaneous adipose tissue throughout the 90-minute tourniquet application. Furthermore, tourniquet-induced tissue ischemia fully resolved 2.5 hours after tourniquet release. Clinical Relevance: Cefuroxime administration 15 to 45 minutes prior to tourniquet inflation seems to be a safe window. If the goal is to maintain postoperative cefuroxime concentrations above relevant MIC values, our results suggest that a second dose of cefuroxime should be administered at the time of tourniquet release.
- Open Access
- 1 March 2020
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 92, 133-140
Population pharmacokinetics of piperacillin in plasma and subcutaneous tissue in patients on continuous renal replacement therapy
- 1 March 2020
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 92, 133-140
Open AccessPopulation pharmacokinetics of piperacillin in plasma and subcutaneous tissue in patients on continuous renal replacement therapy
- 15 March 2016
- Published by Morressier GmbH
Penicillin treatment in infective endocarditis patients – does standard dosing result in therapeutic plasma concentrations?
Welcome to the largest platform for early-stage research
- 15 March 2016
- Published by Morressier GmbH
Penicillin treatment in infective endocarditis patients – does standard dosing result in therapeutic plasma concentrations?
Welcome to the largest platform for early-stage research